Human Immunodeficiency Virus Type 1 (HIV-1) GenoSure Archive

TEST INFORMATION

Test performed at Labcorp Monogram Biosciences, 345 Oyster Point Blvd., South San Francisco, CA 94080

PATIENT REPORT

Patient's results continue on following page(s).
### Generic Name | Brand Name | Assessment | Drug Resistance Associated Mutations Detected | Comments
--- | --- | --- | --- | ---
**NRTI**

*Abacavir* | Zithromax | Resistant | M41L/M, D67D/N, L74I/V, V75V/A, M184V/M, T215T/S/Y | 1

*Didanosine* | Videx | Resistant | M41L/M, D67D/N, L74I/V, V75V/A, M184V/M, T215T/S/Y | 1

*Emtricitabine* | Emtriva | Resistant | M41L/M, D67D/N, M184V/M, T215T/S/Y | 1

*Lamivudine* | Epivir | Resistant | M41L/M, D67D/N, M184V/M, T215T/S/Y | 1

*Stavudine* | Zerit | Resistant | M41L/M, D67D/N, V75V/A, T215T/S/Y | 1

*Tenofovir* | Viread | Resistance Possible | M41L/M, D67D/N, V75V/A, T215T/S/Y | 2

*Zidovudine* | Retrovir | Resistant | M41L/M, D67D/N, V75V/A, T215T/S/Y | 2

**NNRTI**

*Darunavir* | Prezista | Sensitive | None | None

*Efavirenz* | Sustiva | Sensitive | None | None

*Etravirine* | Intercence | Sensitive | None | None

*Nevirapine* | Viramune | Sensitive | None | None

*Rilpivirine* | Edurant | Sensitive | None | None

**IN**

*Bictegravir* | Bictegravir | Sensitive | None | None

*Dolutegravir* | Tivicay | Sensitive | None | None

*Elvitegravir* | Vitekta | Sensitive | None | None

*Raltegravir* | Isentress | Sensitive | None | None

**PI**

*Atazanavir* | Reyataz | Resistant | L10I/V, E55D/E, M36I, M46I/M, I54V/I, V82A/I/T, N88N/S | 3

*Darunavir* | Prezista | Sensitive | L10I/V, M46I/M, V82A/I/T | 3

*Fosamprenavir* | Lexiva | Sensitive | L10I/V, E55D/E, M46I/M, I54V/I, V82A/I/T | 3

*Indinavir* | Crinon | Resistant | L10I/V, M36I, M46I/M, I54V/I, A71V/T, V82V/A/I/T, N88N/S | 3

*Lopinavir* | Kaletra | Resistant | L10I/V, M46I/M, I54V/I, A71V/T, V82V/A/I/T | 3

*Nelfinavir* | Viracept | Resistant | L10I/V, E55D/E, M36I, M46I/M, I54V/I, A71V/T, V82V/A/I/T, N88N/S | 3

*Ritonavir* | Norvir | Resistant | L10I/V, E55D/E, I54V/I, A71V/T, V82V/A/I/T | 3

*Saquinavir* | Invirase | Resistant | L10I/V, E55D/E, I54V/I, A71V/T, N88N/S | 3

*Tipranavir* | Aptivus | Resistant | L10I/V, E55D/E, M36I, M46I/M, I54V/I, V82V/A/I/T | 3

---

Report Version: 15

Page 1 of 2
GenoSure Archive®
HIV-1 Next Generation DNA Sequencing Assay

Weidong Huang, MD, Medical Director
345 Oyster Point Blvd
South San Francisco, CA 94080 - Tel. (800) 777-0177

ARUP Interface Acct
500 Chipeta Way Attn: Referrals MC 233
Salt Lake City, UT 84108
USA

Client: [Redacted] Phone: (800) 242-2787
Project: [Redacted] Fax: (801) 584-5132

Patient Name: [Redacted] DOB: [Redacted] Patient ID/Medical Record #: [Redacted] Gender: M

Monogram Accession #: [Redacted] Report Status: FINAL

Date Collected: 18-MAY-2023 15:43
Date Received: 20-MAY-2023 12:35 PT
Date Reported: 13-JUN-2023 11:11 PT
Mode: F,L,W

* Assessment of drug susceptibility is based on detected mutations and interpreted using an advanced proprietary algorithm (version 18).
+ Interpretation algorithms for ritonavir-boosted protease inhibitors appropriate for the following dosages: AML/300mg/100mg BID; AT/300mg/100mg QD; IDV/800mg/200mg BID; LPV/400mg/100mg BID; SQV/1000mg/100mg BID; TPV/500mg/200mg BID; and DRV/600mg/100mg BID.

* Mixtures are indicated by amino acids separated by a slash. Deletions in the amino acid sequence are indicated by a "-" symbol.

Summary of Mutations Observed
PR  L100I/L134V, E355D/Q, M36I, N370D/I, R414Q/K, M461I, V476G, L694F/P/S, Y71A/T, V82A/I/T, N86I/S

Genotype Comments (clinical significance may vary)
1. Assessment for this drug was derived considering the sensitizing effect of mutation M184V.
2. Assessment for this drug was derived considering the sensitizing effect of mutations L74V and M184V.
3. Assessment for this drug was derived considering the sensitizing effect of mutation N86S.

For more information on interpreting this report, please visit monogrambio.labcorp.com or call Customer Service at 800-777-0177 between the hours of 5:30am to 5:30pm PT Monday through Friday.

GenoSure Archive is a DNA sequencing assay that uses next-generation sequencing to analyze the protease (amino acids 1-99), reverse transcriptase (amino acids 1-400) and integrase (amino acids 1-288) coding regions derived from HIV-1 associated cDNA. Subtype is determined using the protease and reverse transcriptase sequence information. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. Monogram Biosciences, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp. The results should not be used as the sole criteria for patient management. This document contains private and confidential health information protected by state and federal law. If you have received this document in error, please call 800-777-0177.

Report Version: 15

Page 2 of 2

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

END OF CHART
ARUP Enhanced Reporting | June 13, 2023 | page 3 of 3